Core Insights - Apollo Medical Holdings, Inc. has granted equity awards to its newly-hired Chief Medical Officer, Dr. Dinesh M. Kumar, as part of its Employment Inducement Award Plan, which is designed to attract new talent [1][2] Group 1: Equity Awards - The Compensation Committee granted 85,130 shares of time-based restricted common stock and 65,265 shares of performance-based restricted common stock to Dr. Kumar, effective January 23, 2024 [1] - The time-based restricted stock will vest over three years in equal annual installments, while the performance-based stock will vest semi-annually starting July 1, 2024, contingent on performance goals [2] - An additional grant of time-based restricted common stock valued at $250,000 will be awarded to another newly-hired non-executive employee, effective February 5, 2024, also vesting over three years [3] Group 2: Company Overview - ApolloMed is a physician-centric, technology-powered healthcare company focused on enabling providers to deliver value-based care [4] - The company operates an integrated healthcare delivery platform that supports providers in participating in value-based care arrangements, aiming for cost-effective outcomes-based medical care [4] - ApolloMed's subsidiaries include management services organizations and independent practice associations, and it participates in the Centers for Medicare & Medicaid Services Innovation Center models [4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, $0.001 par value per share AMEH The Nasdaq Stock Market LLC FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___. Co ...

Apollo Medical Holdings Inc. (NASDAQ:AMEH) Q3 2023 Earnings Call Transcript November 7, 2023 5:30 PM ET Company Participants Brandon Sim - Co-Chief Executive Officer Chan Basho - Chief Financial Officer Conference Call Participants Ryan Daniels - William Blair Brooks O'Neil - Lake Street Capital Markets Adam Ron - Bank of America David Larsen - BTIG Gary Taylor - TD Cowen Operator Good day, everyone, and welcome to today's Apollo Medical Holdings Third Quarter 2023 Earnings Call. [Operator Instructions]. To ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, $0.001 par value per share AMEH Nasdaq Capital Market FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___. Commission File ...

Financial Data and Key Metrics Changes - The company reported total revenue of $348.2 million in Q2 2023, a 29% increase from $269.7 million in the prior year quarter [15] - Adjusted EBITDA grew by 44% to $35.8 million compared to $24.9 million in the prior year period [19] - Net income attributable to ApolloMed was $13.2 million, a 10% increase from $12 million in Q2 2022 [19] Business Segment Data and Key Metrics Changes - Care Partners segment revenue increased by 32% to $325.2 million, with operating income rising 250% to $27.8 million [15][16] - Care Enablement segment revenue grew by 18% to $35 million, with operating income slightly increasing to $7.6 million [16] - Care Delivery segment revenue increased by 14% to $26.7 million, but operating income decreased to $0.6 million due to ongoing investments [17] Market Data and Key Metrics Changes - Membership under management in the Care Enablement segment was approximately 1.3 million lives, with about 650,000 members also in the Care Partners business [16] - The company continues to grow membership in core California markets and new geographies like Nevada and Texas [14] Company Strategy and Development Direction - The company aims to grow membership in core and new geographies, empower providers towards value-based care, and ensure excellent patient outcomes [6][12] - Recent partnerships and acquisitions, including those in Texas and California, are part of the strategy to expand the Care Partners network [10][11] - The company is focused on expanding its Restricted Knox-Keene license to other counties in California to enhance its risk-based ecosystem [25][49] Management's Comments on Operating Environment and Future Outlook - Management reiterated guidance for full-year 2023, expecting total revenue between $1.3 billion and $1.5 billion and adjusted EBITDA of $120 million to $160 million [22] - The company is monitoring Medicaid redetermination processes but has not seen significant impacts on membership or mix yet [13][29] - Management expressed confidence in the ability to manage through potential rate pressures and changes in supplemental benefits [40] Other Important Information - The company ended Q2 2023 with $294 million in cash and cash equivalents, compared to $288 million at the end of 2022 [22] - A tax-related restatement was noted, which has no impact on historically reported GAAP and non-GAAP measures [20][21] Q&A Session Summary Question: Can you elaborate on the RKK expansion and its timing? - Management is working with the Department of Managed Health Care to expand the Restricted Knox-Keene license to other counties, which involves contracting with payers and provider groups [25] Question: How should we assess the quarterly cadence for adjusted EBITDA going forward? - Management indicated that Q3 is expected to be in line with Q2, with a drop anticipated in Q4 based on historical trends [27] Question: What is the status of Medicaid redeterminations? - Management noted that disenrollments began in July but have not had a material impact yet, and they are actively assisting members [29] Question: Can you provide more details on utilization trends in Q3? - A slight uptick in inpatient Medicare Advantage utilization is expected, but overall Q2 did not see significant increases compared to Q1 [31] Question: What is the expected normalized tax structure? - Management indicated that the effective tax rate is expected to normalize to low to mid-30s, which is higher than the industry average [32][33] Question: Are there any positive impacts from direct contracting or ACO reach? - Management has not incorporated any positive impacts from these programs into their guidance, opting for a conservative approach [35] Question: What is the impact of the IntraCare partnership? - The partnership is expected to add significant revenue, although the exact number of patients and their mix is still being assessed [41][42] Question: What is driving the elevated risk adjustment payments? - The increase is attributed to better capturing chronic conditions in the senior population, which has been a focus of the company's operational improvements [45]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, $0.001 par value per share AMEH Nasdaq Capital Market FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___. Commission File ...

Financial Data and Key Metrics Changes - The company reported total revenue of $337.2 million for Q1 2023, a 28% increase from $263.3 million in the prior year quarter [20][24] - Adjusted EBITDA for the period was $29.8 million, with reported EBITDA of $24 million, up 1.2% from $23.7 million in the prior year [24] - Net income attributable to Apollo Med was $14.6 million, a 3% increase from $14.3 million in Q1 2022, with diluted earnings per share remaining flat at $0.31 [24] Business Segment Data and Key Metrics Changes - Care enablement segment revenue was $30.6 million, a 4% increase from $29.4 million in the prior year, but operating income decreased by 49.3% to $5.7 million due to investments in infrastructure and technology [21] - Care partners segment revenue increased by 30.4% to $314.7 million, with operating income rising 28.2% to $22.3 million, driven by organic membership growth and a favorable payer mix [22] - Care delivery segment revenue rose by 24.9% to $25.4 million, but the segment reported an operating loss of $1 million compared to an operating income of $1.1 million in the prior year due to expansion investments [23] Market Data and Key Metrics Changes - Membership under management in the care enablement segment was approximately 1.3 million, with about 650,000 members also in the care partners business [21] - The company has seen a 120% increase in unique members in newer markets like Nevada and Texas since acquiring Valley Oaks Medical Group [11] Company Strategy and Development Direction - The company is focused on growing membership in core and new geographies, moving members towards global risk contracts, and enabling providers to deliver excellent patient outcomes [10][12] - Recent acquisitions, including For Your Benefit, will allow the company to take on global risk for professional and institutional costs, enhancing its care coordination capabilities [12] - The company is also investing in the care delivery ecosystem through venture investments in innovative solutions for value-based care [14] Management's Comments on Operating Environment and Future Outlook - Management reiterated full-year 2023 guidance for both revenue and net income, emphasizing confidence in growth despite recent developments [18] - The company is streamlining operations and organizational structure to ensure profitability and margins remain on track [17] - Management expressed optimism about the long-term prospects of the business and operational strategy [26] Other Important Information - The company ended Q1 2023 with $274.6 million in cash and cash equivalents, down from $288 million at the end of 2022, while total stockholders' equity increased to $563.2 million [25] - The company repurchased $9.5 million worth of shares during the first quarter as part of a $50 million share repurchase authorization [25] Q&A Session Summary Question: Insights on G&A investments and care enablement - Management discussed investments in analytics and software engineering, which have contributed to increased G&A, and expect revenue to offset these costs in the near future [31][32] Question: Impact of Medicaid redetermination - Management indicated that the impact of Medicaid redetermination is included in guidance, with expectations to capture many members during the process [35] Question: LaSalle Medical Group contract termination - The termination was due to pricing terms not supporting long-term margins, which are typically in the 20% to 30% range [38] Question: Workforce trimming and Medicare pressures - Management confirmed a potential 5% workforce reduction to ensure robust margins in the care enablement business, with no significant pressure observed in the Medicare segment [42] Question: Opportunities with the Restricted Knox-Keene license - Management highlighted plans to operationalize the license across California, expecting initial breakeven results with long-term margin alignment [46][49] Question: ACO REACH program performance - Management noted that the ACO REACH program is currently breakeven, with ongoing evaluations to determine its long-term viability [56] Question: Timing for converting capitated lives under Knox-Keene - Management indicated that the conversion will be phased in over the next 18 to 24 months, with expectations for gradual revenue and EBITDA growth [59][61]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from ___ to ___ . Commission file number: 001-37392 Apollo Medical Holdings, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of i ...